Vertex Pharmaceuticals' unchanged guidance and disappointing trial outcomes for its investigative pain relief treatment led ...

Vertex Pharmaceuticals' Seaport headquarters buildings have been refinanced for $1 billion, putting a ten-figure value on an ...

The heritage British brand has been revived by a chairman whose impressive career before watchmaking includes a three-year ...

Vertex Pharmaceuticals ( VRTX) plunged after Q2 earnings and is now down 21% over the past year. The company has historically ...

The RMR Group (Nasdaq: RMR) today announced on behalf of its managed joint venture that it has facilitated a $1.0 billion ...

Vertex Pharmaceuticals Incorporated's stock drop is overblown. With strong CF revenue, pipeline potential, & insider ...

A federal judge ruled Hampton’s Zoning Board had ample evidence to reject the tower, but left one legal claim standing.

The RMR Group secured a $1 billion refinancing for Vertex Pharmaceuticals' Boston Seaport headquarters, a five-year, interest ...

Vertex Pharmaceuticals’ second quarter 2025 results exceeded Wall Street’s expectations, but the market responded sharply ...

ELIVAAS plans to utilise the funds to expand its presence in India, increase operations in high-demand leisure and business ...

Vertex Corp. (5290.TO) Japan 1st Quarter Ended June 30 GROUP 2025 2024 Revenue Y8.70 bln Y8.24 bln Operating Profit Y1.08 bln Y781.00 mln Pretax Profit Y1.15 bln Y830.00 mln Net Profit Y658.00 mln ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $200.0 and $460.0 for Vertex Pharmaceuticals, spanning the last ...